Hepatitis C virus non-structural proteins (NS proteins) (HCV NS proteins)

Hepatitis C virus (HCV) non-structural (NS) proteins, including NS2, NS3, NS4A, NS4B, NS5A, and NS5B, are essential components of the viral replication machinery and are the primary targets for both therapeutic and prophylactic interventions (Source: UniProt P26664). NS3/4A functions as a serine protease and helicase, NS5A is a multifunctional phosphoprotein involved in viral assembly and interferon resistance, and NS5B is the RNA-dependent RNA polymerase responsible for genome replication (Source: NIH/NCBI Bookshelf NBK551549). In the context of vaccine development, these proteins are highly valued as antigens because they contain conserved T-cell epitopes that can trigger robust CD4+ and CD8+ T-cell responses across multiple HCV genotypes (Source: PubMed PMID: 31404141). While direct-acting antivirals (DAAs) targeting NS3, NS5A, and NS5B have achieved high cure rates, a vaccine targeting these non-structural proteins is considered necessary to prevent reinfection and achieve global elimination of the virus (Source: PubMed PMID: 33165473). Therapeutic challenges include the emergence of resistance-associated substitutions (RASs) and the high genetic diversity of HCV, which necessitates the inclusion of multiple conserved regions in vaccine designs (Source: PubMed PMID: 28881762).

Other names

HCV non-structural proteinsHCV NS proteinsNS2-NS5B polyproteinHCV replication complex proteinsHCV NS3/4A, NS5A, and NS5B

Inhibition of viral NS3/4A protease, NS5A protein, and NS5B RNA-dependent RNA polymerase to block viral replication and assembly; induction of T-cell mediated immune responses against conserved viral epitopes (Source: NIH/NCBI Bookshelf NBK551549, PubMed PMID: 31404141).